Aclaris completes $65M deal for rosacea treatment
Malvern-based Aclaris Therapeutics Inc. completed its previously announced $65 million acquisition of Rhofade, a rosacea treatment, from Allergan.
The Food and Drug Administration approved Rhofade, a cream, last year as topical treatment of persistent facial erythema or redness associated with rosacea in adults.
“ An estimated 16 million American adults have rosacea, yet only a small fraction of that number seeks professional care," said Dr. Neal Walker, president and CEO of Aclaris (NASDAQ:…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Allergy | Biotechnology | Food and Drug Administration (FDA) | Health Management | Mergers and Aquisitions | Rosacea